



## Selection criteria for intrarenal pressure sensing ureteroscopes



PERSPECTIVE BY

**Naeem Bhojani  
MD, FRCS**

Associate Professor  
of Urology,  
Montreal, Canada

### Risk factors for postoperative infection after ureteroscopy

With recent advancements in technology, ureteroscopy (URS) has become the primary surgical treatment modality for upper tract kidney stones.<sup>1,2</sup>

Recent studies have demonstrated that the risk of infection and even sepsis after URS may be significant. Our recent meta-analysis and systematic review found a 5.0% pooled incidence of postoperative urosepsis (95% CI, 2.4-8.2)<sup>3</sup> and our recent large retrospective study (n=104,100) of commercially insured U.S. patients reported a 5.5% rate of sepsis post-URS.<sup>4</sup> This risk may seem low. However, considering there is a 10.1% prevalence rate of kidney stone disease in the U.S. (based on 2013-2014 data)<sup>5</sup> and the impact on healthcare utilization and cost,<sup>4</sup> it becomes a significant outcome that requires considerable consideration.

To reduce the risk of post-URS infectious complications, including sepsis, there are a number of risk factors to consider:

#### **Our systematic review and meta-analysis identified the following risk factors associated with increased postoperative urosepsis risk:<sup>3</sup>**

- Preoperative ureteral stent (OR=3.94; 95% CI, 2.36-6.60)
- Preoperative positive urine culture (OR=3.56; 95% CI, 2.11-6.01)
- Comorbidities: ischemic heart disease (OR=2.49; 95% CI, 1.38-4.48), diabetes (OR=2.04; 95% CI, 1.04-4.03)
- Longer procedure time (mean difference=9 min; 95% CI, 2-16,  $p=0.02$ )
- Older age (mean difference=2.7 years; 95% CI, 1.0-4.4,  $p=0.002$ )

#### **Our retrospective study identified the following risk factors for sepsis post-URS, in addition to many of those identified in our meta-analysis:<sup>4</sup>**

- History of sepsis in 6 months prior to index URS (OR=3.51; 95% CI, 3.08-3.99)
- Hospitalization in 6 months prior to index URS (OR=1.17; 95% CI, 1.06-1.29)

#### **Additionally, in a 2020 systematic review, the following were associated with infectious complications after URS:<sup>6</sup>**

- Neurogenic bladder
- Female gender

**Finally, struvite stones are embedded with gram-negative bacteria**, which can produce endotoxin.<sup>7</sup> A retrospective study showed an association between struvite stones and systemic inflammatory response syndrome (SIRS) (OR=3.331; 95% CI, 0.971-11.426).<sup>8</sup> SIRS is a serious condition closely associated with sepsis.<sup>9</sup>

## Risk factors for postoperative infection after URS (cont.)


A number of studies have demonstrated that irrigation-related factors are associated with postoperative infection and SIRS.<sup>8,10,11</sup> One of these studies was a randomized single-blind clinical trial comparing pressure irrigation at 80 mmHg vs. 200 mmHg during percutaneous nephrolithotomy (PCNL).<sup>11</sup> It was determined that the higher-pressure irrigation was an independent predictor of SIRS postoperatively. Increased irrigation pressure has been shown to result in increased intrarenal pressure.<sup>12</sup>

Other than the type of irrigation (pressure vs. non-pressurized) being used, additional factors can impact intrarenal pressure. Specifically for sepsis and intrarenal pressure, one factor to consider is the use of a ureteral access sheath (UAS). While there are risks associated with using a UAS, research suggests that the use of a UAS can reduce the risk of postoperative sepsis<sup>13</sup> (although this hasn't been found in all studies).<sup>14</sup> It is theorized that this is most likely due to the reduction in intrarenal pressure associated with the use of a UAS.<sup>15,16</sup>

## Significant evolution in flexible ureteroscope technology

Since the introduction of the flexible ureteroscope, advancements continue to make them smaller, more maneuverable, and with better image resolution. The flexible ureteroscope has revolutionized the way we treat kidney stones.<sup>17</sup> The launch of the first single-use ureteroscope in 2016 established a new paradigm in the surgical management of kidney stone disease in terms of access, indication, and financial costs for both the healthcare ecosystem and surgeons.<sup>18</sup> Boston Scientific pioneered this movement with the introduction of the LithoVue™ Single-Use Digital Flexible Ureteroscope. Since then, new innovations in chip technology, camera image quality, and maneuverability have brought about a new generation of single-use ureteroscopes across the globe.


The LithoVue™ Elite Single-Use Digital Flexible Ureteroscope, the latest innovation from Boston Scientific, builds on the LithoVue™ Single-Use Digital Flexible Ureteroscope and is the first and only ureteroscope with real-time pressure monitoring. Additionally, the LithoVue Elite Ureteroscope improves upon essential functionalities such as camera image quality.



## Selective approach

Similar to the [criteria](#) developed for single-use ureteroscopes in specific cases (i.e., large lower pole stone burden), facilities may benefit from using a clinical decision pathway tool to help decide when to use a pressure sensing ureteroscope.

Consider using the LithoVue Elite Ureteroscope in patients at risk of postoperative infectious complications, including sepsis, using the following selection pathway to potentially maximize the benefits at your institution:



\*These factors have been associated with high risk (>3.0 odds ratio indicated in literature) of postoperative infectious complications following URS.

## References

1. Oberlin DT, Flum AS, Bachrach L, Matulewicz RS, Flury SC. Contemporary surgical trends in the management of upper tract calculi. *J Urol*. 2015 Mar;193(3):880-4.
2. Ordon M, Urbach D, Mamdani M, et al. The surgical management of kidney stone disease: a population based time series analysis. *J Urol*. 2014 Nov;192(5):1450-6.
3. Bhojani NB, Miller LE, Bhattacharyya S, et al. Risk factors for urosepsis after ureteroscopy for stone disease: a systematic review with meta-analysis. *J Endourol*. 2021 Jul;35(7):991-1000.
4. Bhojani N, Paranjpe R, Cutone B, et al. Predictors and healthcare utilization of sepsis post-ureteroscopy in a US-based population: results from the Endourological Society TOWER collaborative. *J Endourol*. 2022 Oct 5. Online ahead of print.
5. Chen Z, Proserpi M, Bird VY. Prevalence of kidney stones in the USA: The National Health and Nutrition Evaluation Survey. *J Clin Urol*. 2019;12(4):296-302.
6. Chugh S, Pietropaolo A, Montanari E, et al. Predictors of urinary infections and urosepsis after ureteroscopy for stone disease: a systematic review from EAU section of urolithiasis (EULIS). *Curr Urol Rep*. 2020 Mar 24;21(4):16.
7. McAleer IM, Kaplan GW, Bradley JS, Carroll SF. Staghorn calculus endotoxin expression in sepsis. *Urology*. 2002 Apr;59(4):601.
8. Zhong W, Leto G, Wang L, Zeng G. Systemic inflammatory response syndrome after flexible ureteroscopic lithotripsy: a study of risk factors. *J Endourol*. 2015 Jan;29(1):25-8.
9. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. *Chest*. 1992 Jun;101(6):1644-55.
10. Farag M, Timm B, Davis N, et al. Pressurized-bag irrigation versus hand-operated irrigation pumps during ureteroscopic laser lithotripsy: Comparison of infectious complications. *J Endourol*. 2020 Sep;34(9):914-8.
11. Omar M, Noble M, Sivalingam S, et al. Inflammatory response syndrome after percutaneous nephrolithotomy: a randomized single-blind clinical trial evaluating the impact of irrigation pressure [published correction appears in *J Urol*. 2017 May;197(5):1365]. *J Urol*. 2016 Jul;196(1):109-14.
12. Wilson WT, Preminger GM. Intrarenal pressures generated during flexible deflectable ureterorenoscopy. *J Endourol*. 1990;4(2):135-41.
13. Traxer O, Wendt-Nordahl G, Sodha H, et al. Differences in renal stone treatment and outcomes for patients treated either with or without the support of a ureteral access sheath: The Clinical Research Office of the Endourological Society Ureteroscopy Global Study. *World J Urol*. 2015 Dec;33(12):2137-44.
14. Damar E, Senocak C, Ozbek R, et al. Does ureteral access sheath affect the outcomes of retrograde intrarenal surgery: a prospective study. *Minim Invasive Ther Allied Technol*. 2022 Jun;31(5):777-81.
15. Auge BK, Pietrow PK, Lallas CD, et al. Ureteral access sheath provides protection against elevated renal pressures during routine flexible ureteroscopic stone manipulation. *J Endourol*. 2004 Feb;18(1):33-6.
16. Rehman J, Monga M, Landman J, et al. Characterization of intrapelvic pressure during ureteropyeloscopy with ureteral access sheaths. *Urology*. 2003 Apr;61(4):713-8.
17. Butticiè S, Sener TE, Netsch C, et al. LithoVue™: A new single-use digital flexible ureteroscope. *Cent European J Urol*. 2016;69(3):302-5.
18. Dale J, Kaplan AG, Radvak D, et al. Evaluation of a novel single-use flexible ureteroscope. *J Endourol*. 2021 Jun;35(6):903-7.

Bench Test or pre-clinical study results may not necessarily be indicative of clinical outcomes.

Naeem Bhojani, MD, is a Boston Scientific consultant and was compensated for his contribution to this article.

**IMPORTANT INFORMATION:** These materials are intended to describe common clinical considerations and procedural steps for the use of referenced technologies but may not be appropriate for every patient or case. Decisions surrounding patient care depend on the physician's professional judgment in consideration of all available information for the individual case. Boston Scientific (BSC) does not promote or encourage the use of its devices outside their approved labeling. Case studies are not necessarily representative of clinical outcomes in all cases as individual results may vary.

**CAUTION:** U.S. Federal law restricts this device to sale by or on the order of a physician.

All images are the property of Boston Scientific. All trademarks are the property of their respective owners.

**Boston  
Scientific**  
Advancing science for life™

Boston Scientific Corporation  
300 Boston Scientific Way  
Marlborough, MA 01752-1234  
www.BostonScientific.com

©2022 Boston Scientific Corporation  
or its affiliates. All rights reserved.

URO-1411104-AA NOV 2022